Medicinal product containing the active substance ocrelizumab

Summary

The tender concerns the supply of medicinal products containing the active substance ocrelizumab. The buyer intends to conclude a framework purchase agreement for supplies according to its needs. The notice states that the bid must be submitted electronically and that e-invoicing or an electronic process is required. No precise qualification or exclusion requirements were provided in the machine-readable notice, so they must be checked in the tender documents.